We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors

By MedImaging International staff writers
Posted on 05 Jan 2024
Print article
Image: A research team has drawn up criteria for PET-based examinations of malignant brain tumors (Photo courtesy of 123RF)
Image: A research team has drawn up criteria for PET-based examinations of malignant brain tumors (Photo courtesy of 123RF)

Diffuse gliomas, which are aggressive malignant brain tumors originating from glial cells, present significant treatment challenges. Standard magnetic resonance imaging (MRI) techniques do not adequately capture the complexity of diffuse gliomas. Instead, amino acid positron emission tomography (PET) has become a crucial tool in diagnosing these tumors. This method utilizes protein-based tracers (amino acids) that accumulate in brain tumors, offering more accurate insights into the activity and extent of gliomas. Despite its extensive use in neuro-oncology for years, amino acid PET had not undergone systematic evaluation, and unlike MRI diagnostics, there have been no established criteria for interpreting these PET images.

Now, the international Response Assessment in Neuro-Oncology (RANO) Working Group, guided by experts from Ludwig Maximilian University of Munich (LMU, Munich, Germany) and the Medical University of Vienna (Vienna, Austria), has introduced the first-ever global standards for gliomas imaging using amino acid PET. The RANO Working Group, a diverse international consortium with a decade-long history of developing criteria to serve as standard references for brain tumor-related clinical studies, has made significant strides in assessing various critical clinical aspects.

The RANO group has formulated PET RANO 1.0, a set of criteria aimed at evaluating the effectiveness of treatments for diffuse gliomas using PET. These PET-based standards usher in novel avenues for the uniform assessment of diffuse gliomas. The researchers believe that these new criteria not only facilitate the use of PET in clinical trials and routine practice but also lay a solid groundwork for future investigations, fostering the comparison and enhancement of treatment modalities for better therapeutic outcomes.

Related Links:
LMU
Medical University of Vienna

Opaque X-Ray Mobile Lead Barrier
2594M
Mini C-arm Imaging System
Fluoroscan InSight FD
Diagnostic Ultrasound System
MS1700C
New
MRI System
Ingenia Prodiva 1.5T CS

Print article

Channels

Ultrasound

view channel
Image: The novel method of fighting cancer can stimulate critical cytokine secretion in T cells

Ultrasound-Directed Microbubbles Boost Immune Response Against Tumors

A significant challenge in cancer treatment is the tumor's ability to suppress the immune system, particularly by deactivating T cells that enter the tumor. Once inside, the tumor can inhibit T cells from... Read more

Nuclear Medicine

view channel
Image: PSMA-PET/CT images of an 85-year-old patient with hormone-sensitive prostate cancer (Photo courtesy of Dr. Adrien Holzgreve)

Advanced Imaging Reveals Hidden Metastases in High-Risk Prostate Cancer Patients

Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) imaging has become an essential tool in transforming the way prostate cancer is staged. Using small amounts of radioactive “tracers,”... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.